Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Neuroblastoma 3Melanoma 3Uterine Cervical Neoplasms 2Nasopharyngeal Carcinoma 2Lymphoma, Non-Hodgkin 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Hepatocellular 2Breast Neoplasms 2Stomach Neoplasms 1Solid Tumors 1Solid Tumor 1Recurrence 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Lymphoma, T-Cell 1Lymphoma, Large B-Cell, Diffuse 1Leukemia, Lymphocytic, Chronic, B-Cell 1Hodgkin Disease 1Head and Neck Neoplasms 1Carcinoma, Renal Cell 1Carcinoma 1Anus Neoplasms 1Advanced Refractory Solid Tumors 1Advanced Malignant Solid Tumor 1

Interventions

Radiation Dose Hypofractionation 1N-(4-(3-(1H-1,2,4-triazol-1-yl)-4-(3,4,5-trimethoxybenzoyl)phenyl)thiazol-2-yl)-2-amino-3-methylbutanamide 1Interleukin-2 1Immune Checkpoint Inhibitors 1Granulocyte-Macrophage Colony-Stimulating Factor 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × Advanced Refractory Solid Tumors × Interleukin-2 × Clear all
NCT04892498 2022-08-09

Hypofractionated Radiotherapy Combined With PD-1 Inhibitor Sequential GM-CSF and IL-2 for the Treatment of Advanced Refractory Solid Tumors (PRaG2.0)

Second Affiliated Hospital of Soochow University

Phase 2 Unknown
66 enrolled
Other solid neoplasm

Advanced Refractory Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡